The Battle Over Neulasta Biosimilars in the US: What's Coming in 2018
By Zachary Brennan -
Published 18 January 2018
2016 and 2017 were difficult years for companies trying to win US Food and Drug Administration (FDA) approval for biosimilars of Amgen's blockbuster for treating side effects from chemotherapy.
Categories: News, US, FDA, Regulatory intelligence, Regulatory strategy
Tags: Neulasta, Mylan, Coherus, Amgen, 340B